John Green

John Green is the current CFO at Cogent Biosciences. Prior to joining Cogent Biosciences, John was the Corporate Controller and Principal Accounting Officer at Merrimack Pharmaceuticals from March 2017 to June 2018. During their tenure at Merrimack, the Company went through a $1.025 billion Asset Sale of a commercial pancreatic cancer drug Onivyde and subsequently de-commercialized their commercial product and downsizing of the organization. This resulted in various complex technical accounting, reporting and operational issues which John led the finance team through during this transition and stepped into the interim CFO responsibilities including Principal Accounting Officer.

Prior to joining Merrimack Pharmaceuticals, John served as the Controller at Fractyl Laboratories Inc. from November 2015 to March 2017 and as Director of Accounting at Dicerna Pharmaceuticals, Inc. from June 2014 to November 2015. Earlier in their career, John was a Senior Manager at CFGI from November 2013 to June 2014 and a Manager at PricewaterhouseCoopers from April 2008 to September 2013.

John Green's educational career includes a Bachelor of Science in Chemistry & Biology from Acadia University and a Chartered Accountant designation from the Atlantic School of Chartered Accountancy.

Some of their coworkers include Brad Barnett - Chief Technology Officer, John Robinson - Chief Scientific Officer, and Erin Schellhammer - Chief People Officer. Their manager is Andrew Robbins, CEO & President.